Central nervous system immune surveillance: On natalizumab, dendritic cells, and dangerous immune privilege

Archives of Neurology

Volumn 65, Issue 12, 2008, Pages 1566-1567

  Becher, Burkhard ^a  

^a INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; VERY LATE ACTIVATION ANTIGEN 4;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; DENDRITIC CELL; DRUG HALF LIFE; EDITORIAL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; LEUKOENCEPHALOPATHY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM; DENDRITIC CELLS; HUMANS; IMMUNOLOGIC SURVEILLANCE;

EID: 61449098529     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.12.1566     Document Type: Editorial

References (8)

1. Steinman L, Martin R, Bernard C, Conlon P, Oksenberg JR. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci. 2002;25:491-505.
2. Kieseier BC, Wiendl H, Hemmer B, Hartung HP. Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol. 2007;20(3):286-293.
3. MullerWA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol. 2003;24(6):327-334.
4. Yednock TA, Cannon C, FritzLC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992;356(6364):63-66.
5. + T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol. 2008;65(12):1596-1603.
6. Greter M, Heppner FL, Lemos MP, et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med. 2005;11(3):328-334.
7. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59(5):743-747.
8. + T-cell ratios in cerebro-spinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006;63(10):1383-1387.